IL17A and colitis: Baseline IL-17 serum levels may predict ICI-induced colitis in patients with melanoma treated with ipilimumab (65).Baseline IL-6 serum levels were associated with higher risk of toxicity in melanoma patients treated with ipilimumab (111).Cytokine toxicity score predictive of severe irAEs in patients with melanoma treated with ipilimumab, anti-PD-1 or their combination (112).Baseline serum levels of IL-1β, IL-2, and GM-CSF predict thyroid dysfunction in patients with a variety of cancers (66).